Is AbbVie (NYSE:ABBV) A Risky Investment?
According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.
AbbVie Inc. (NYSE:ABBV) is largely controlled by institutional shareholders who own 73% of the company
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...
The New York Times5d
AbbVie Inc
Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much. With a $21 billion deal, the pharmaceutical ...
stocknews4d
3 High-Dividend Pharma Blue Chips That Are on Sale Right Now
With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...
pharmaphorum1d
A history of Abbott and AbbVie
Vysis, Inc., a leading genomic disease management ... a new researched-based global biopharmaceutical company – AbbVie. In January 2013, AbbVie was formed. It began trading independently on ...
iTeos Therapeutics (ITOS) Receives a Buy from Piper Sandler
Piper Sandler analyst Christopher Raymond maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report) today and set a price ...
Nuvalent (NUVL) Receives a Buy from Piper Sandler
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Nuvalent (NUVL – Research Report) today and set a price target of ...
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...